📊 BGM Key Takeaways
Is BGM Group Ltd. (BGM) a Good Investment?
BGM Group Ltd. presents an unanalyzable investment case due to complete absence of SEC financial data. No revenue, profitability, balance sheet, or cash flow metrics are available, making fundamental analysis impossible. Without financial disclosure, investor risk cannot be assessed.
BGM’s SEC filings show weak core fundamentals: revenue fell sharply from $64.9 million in FY2022 to $25.1 million in FY2024, and the company remained loss-making with negative operating income in both FY2023 and FY2024. While the six months ended March 31, 2025 showed headline revenue growth from acquisitions and a stronger gross margin, operating losses widened, operating cash flow turned negative, and the balance sheet became heavily dependent on newly issued equity and goodwill rather than internally generated earnings.
Why Buy BGM Group Ltd. Stock? BGM Key Strengths
- Listed on Nasdaq, suggesting minimum regulatory compliance requirements met
- Pharmaceutical sector has potential for high-margin products
- Theoretically positioned in healthcare industry with structural growth trends
- Gross margin improved from 3.8% in FY2023 to 16.4% in FY2024 and about 17.5% in the six months ended March 31, 2025
- Liquidity remained adequate as of March 31, 2025, with cash of about $9.7 million and current assets well above current liabilities
- Long-term financial leverage remained relatively low, with limited balance-sheet debt compared with reported equity
BGM Stock Risks: BGM Group Ltd. Investment Risks
- No financial data available - inability to assess solvency or operational performance
- Zero insider activity in last 90 days - potential lack of management confidence or engagement
- Appears to be non-reporting or shell company status - severe transparency and information risk
- Core earnings quality is weak, with recurring operating losses and net losses despite recent revenue contributions from acquired businesses
- Growth appears acquisition-driven and comes with major integration risk, including a large goodwill build and a much more complex balance sheet
- Operating cash flow deteriorated to a $3.1 million outflow in the latest interim period, alongside sharp increases in accounts receivable and inventory
Key Metrics to Watch
- SEC financial filing submission and revenue recognition
- Balance sheet capitalization and cash position
- Operating cash flow and R&D spending as percentage of revenue
- Organic revenue growth and segment operating profitability, especially in the pharmaceutical business
- Operating cash flow conversion, with close attention to accounts receivable, inventory, and goodwill-related impairment risk
BGM Group Ltd. (BGM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BGM Profit Margin, ROE & Profitability Analysis
BGM vs Healthcare Sector: How BGM Group Ltd. Compares
How BGM Group Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BGM Group Ltd. Stock Overvalued? BGM Valuation Analysis 2026
Based on fundamental analysis, BGM Group Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BGM Group Ltd. Balance Sheet: BGM Debt, Cash & Liquidity
BGM Revenue Growth, EPS Growth & YoY Performance
BGM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BGM Group Ltd. (CIK: 0001779578)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGM
What is the AI rating for BGM?
BGM Group Ltd. (BGM) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGM's key strengths?
Claude: Listed on Nasdaq, suggesting minimum regulatory compliance requirements met. Pharmaceutical sector has potential for high-margin products. ChatGPT: Gross margin improved from 3.8% in FY2023 to 16.4% in FY2024 and about 17.5% in the six months ended March 31, 2025. Liquidity remained adequate as of March 31, 2025, with cash of about $9.7 million and current assets well above current liabilities.
What are the risks of investing in BGM?
Claude: No financial data available - inability to assess solvency or operational performance. Zero insider activity in last 90 days - potential lack of management confidence or engagement. ChatGPT: Core earnings quality is weak, with recurring operating losses and net losses despite recent revenue contributions from acquired businesses. Growth appears acquisition-driven and comes with major integration risk, including a large goodwill build and a much more complex balance sheet.
What is BGM's revenue and growth?
BGM Group Ltd. reported revenue of N/A.
Does BGM pay dividends?
BGM Group Ltd. does not currently pay dividends.
Where can I find BGM SEC filings?
Official SEC filings for BGM Group Ltd. (CIK: 0001779578) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGM's EPS?
BGM Group Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BGM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BGM Group Ltd. has a SELL rating with 44% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BGM stock overvalued or undervalued?
Valuation metrics for BGM: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BGM stock in 2026?
Our dual AI analysis gives BGM Group Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BGM's free cash flow?
BGM Group Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does BGM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).